Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cancer Genetics stock

Own Cancer Genetics stock in just a few minutes.

Cancer Genetics, Inc is a biotechnology business based in the US. Cancer Genetics shares (CGIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cancer Genetics employs 110 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cancer Genetics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CGIX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cancer Genetics share price

Use our graph to track the performance of CGIX stocks over time.

Cancer Genetics shares at a glance

Information last updated 2021-04-25.
52-week range$2.11 - $7.70
50-day moving average $5.82
200-day moving average $3.97
Wall St. target price$3.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.52

Buy Cancer Genetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cancer Genetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cancer Genetics financials

Revenue TTM $6.3 million
Gross profit TTM $3.6 million
Return on assets TTM -14.9%
Return on equity TTM -68.71%
Profit margin -71.5%
Book value $1.92
Market capitalisation $48.7 million

TTM: trailing 12 months

Shorting Cancer Genetics shares

There are currently 723,746 Cancer Genetics shares held short by investors – that's known as Cancer Genetics's "short interest". This figure is 46.4% up from 494,219 last month.

There are a few different ways that this level of interest in shorting Cancer Genetics shares can be evaluated.

Cancer Genetics's "short interest ratio" (SIR)

Cancer Genetics's "short interest ratio" (SIR) is the quantity of Cancer Genetics shares currently shorted divided by the average quantity of Cancer Genetics shares traded daily (recently around 1.3 million). Cancer Genetics's SIR currently stands at 0.56. In other words for every 100,000 Cancer Genetics shares traded daily on the market, roughly 560 shares are currently held short.

However Cancer Genetics's short interest can also be evaluated against the total number of Cancer Genetics shares, or, against the total number of tradable Cancer Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cancer Genetics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cancer Genetics shares in existence, roughly 70 shares are currently held short) or 0.0691% of the tradable shares (for every 100,000 tradable Cancer Genetics shares, roughly 69 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cancer Genetics.

Find out more about how you can short Cancer Genetics stock.

Cancer Genetics share dividends

We're not expecting Cancer Genetics to pay a dividend over the next 12 months.

Have Cancer Genetics's shares ever split?

Cancer Genetics's shares were split on a 1:30 basis on 24 October 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cancer Genetics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Cancer Genetics shares which in turn could have impacted Cancer Genetics's share price.

Cancer Genetics share price volatility

Over the last 12 months, Cancer Genetics's shares have ranged in value from as little as $2.1076 up to $7.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cancer Genetics's is 2.7237. This would suggest that Cancer Genetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cancer Genetics overview

Cancer Genetics, Inc. , through its subsidiary, vivoPharm, Pty Ltd. , provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site